Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials

Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates

(2014) Oliver Ristow et al.   BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY

Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis

(2014) John W. Hellstein et al.   JOURNAL OF THE AMERICAN DENTAL ASSOCIATION

Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study

(2013) C. Roux et al.   BONE

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial

(2013) Joy N Tsai et al.   LANCET

Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study

(2013) Sant Chawla et al.   LANCET ONCOLOGY

Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy

(2013) Chris Recknor et al.   OBSTETRICS AND GYNECOLOGY

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

(2013) David Henry et al.   SUPPORTIVE CARE IN CANCER

Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid

(2012) M. Martin et al.   CLINICAL CANCER RESEARCH

A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density

(2012) Eric Orwoll et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study

(2012) Giorgio Vittorio Scagliotti et al.   Journal of Thoracic Oncology

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

(2011) F. Saad et al.   ANNALS OF ONCOLOGY

A randomized, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of denosumab administered subcutaneously to postmenopausal Japanese women

(2011) Yuji Kumagai et al.   BONE

Denosumab for the Reduction of Bone Loss in Postmenopausal Osteoporosis: A Review

(2011) Mary Barna Bridgeman et al.   CLINICAL THERAPEUTICS

The role and efficacy of denosumab in the treatment of osteoporosis: an update

(2011) Ioannis Charopoulos et al.   Expert Opinion On Drug Safety

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

(2011) Michael R McClung et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of denosumab on fracture and bone mineral density by level of kidney function

(2011) Sophie A Jamal et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

(2011) Socrates Papapoulos et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

(2011) David H. Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

(2011) Karim Fizazi et al.   LANCET

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

(2011) Matthew R Smith et al.   LANCET

Dose–response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis

(2011) T. Nakamura et al.   OSTEOPOROSIS INTERNATIONAL

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?

(2011) N. B. Watts et al.   OSTEOPOROSIS INTERNATIONAL

Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

(2011) N. Freemantle et al.   OSTEOPOROSIS INTERNATIONAL

RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?

(2011) Tim Van den Wyngaert et al.   SUPPORTIVE CARE IN CANCER

Microarchitectural deterioration of cortical and trabecular bone: Differing effects of denosumab and alendronate

(2010) Ego Seeman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial

(2010) Paul D. Miller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

(2010) Alison T. Stopeck et al.   JOURNAL OF CLINICAL ONCOLOGY

Osteonecrosis of the Jaw in a Patient on Denosumab

(2010) Tara L. Aghaloo et al.   JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

(2010) D. L. Kendler et al.   OSTEOPOROSIS INTERNATIONAL

An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma

(2009) Ravi Vij et al.   AMERICAN JOURNAL OF HEMATOLOGY

Osteonecrosis of the jaws induced by anti-RANK ligand therapy

(2009) K.H. Taylor et al.   BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

(2009) David L Kendler et al.   JOURNAL OF BONE AND MINERAL RESEARCH

The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data

(2009) Matthew R. Allen et al.   JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

(2009) Matthew R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

(2008) Stanley B. Cohen et al.   ARTHRITIS AND RHEUMATISM

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial

(2008) Paul D. Miller et al.   BONE

Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases

(2008) Kan Yonemori et al.   CANCER SCIENCE

Clinical Potential of RANKL Inhibition for the Management of Postmenopausal Osteoporosis and Other Metabolic Bone Diseases

(2008) Pierre D. Delmas   JOURNAL OF CLINICAL DENSITOMETRY

Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women

(2008) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer

(2008) Georgiana K. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY